Volume 29, Number 9—September 2023
Research
COVID-19 Epidemiology during Delta Variant Dominance Period in 45 High-Income Countries, 2020–2021
Christine J. Atherstone
, Sarah Anne J. Guagliardo, Anthony Hawksworth, Kevin O’Laughlin, Kimberly Wong, Michelle L. Sloan, Olga Henao, Carol Y. Rao, Peter D. McElroy, and Sarah D. Bennett
, Sarah Anne J. Guagliardo, Anthony Hawksworth, Kevin O’Laughlin, Kimberly Wong, Michelle L. Sloan, Olga Henao, Carol Y. Rao, Peter D. McElroy, and Sarah D. Bennett
Table 1
Descriptive statistics for COVID-19 outcomes and predictor variables in Delta dominance period and pre-Delta period for 45 high-income countries, December 2020–November 2021*
| Outcome variables: peak rate ratios† | Min | Mean | Median | Peak | IQR |
|---|---|---|---|---|---|
| Cases | 0.06 | 1.4 | 1.2 | 4.2 | 0.65–1.91 |
| Deaths | 0.05 | 2.9 | 0.49 | 99 | 0.25–0.93 |
| CFR |
0.00 |
0.21 |
0.08 |
2.3 |
0.02–0.27 |
| Predictor variables | |||||
| % Vaccination coverage‡ | 1.0 | 32 | 31 | 72 | 24–37 |
| % Population >65 y of age | 1.1 | 16 | 18 | 27 | 14–20 |
| Population density, persons/km2 | 3.2 | 544 | 123 | 7,916 | 36–237 |
| Median stringency index† | 0.5 | 0.86 | 0.78 | 3.5 | 0.67–0.90 |
| Median daily testing volume† | 0.6 | 2.3 | 1.7 | 19.2 | 1.2–2.4 |
*CFR, case-fatality rate; IQR, interquartile range. †Delta dominance (DD) period to pre-Delta period ratio. ‡Indicates persons with primary vaccine series at date of Delta predominance.
Page created: July 11, 2023
Page updated: August 20, 2023
Page reviewed: August 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.